Fingerprint
Dive into the research topics of 'Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months
Precise 3 Study Investigators